US Judge Calls Proposed Bayer Roundup Settlement a “Filthy” Deal

Key Takeaways

• Judge Chhabria labeled $7.25 B deal “filthy” and procedurally flawed.
• Settlement filed in Missouri without notice to opposing plaintiffs’ counsel.
• Bayer has already spent over $11 B on Roundup verdicts and settlements.
• Opt‑out process described as “onerous, unfair, possibly unconstitutional.”
• Supreme Court’s pending preemption ruling could reshape future glyphosate liability.

Pulse Analysis

Bayer’s Roundup litigation has become a textbook case of how a single product can generate a cascade of legal exposure. The company inherited Monsanto’s liability for glyphosate, a herbicide the EPA deems unlikely to cause cancer, yet juries across the United States have awarded billions to plaintiffs alleging cancer links. Multidistrict litigation in the Northern District of California now consolidates roughly 60,000 pending claims, and the firm has already disbursed more than $11 billion in settlements and verdicts. This backdrop explains why Bayer is aggressively pursuing a $7.25 billion class‑action deal to cap its obligations.

The proposed settlement’s procedural flaws have drawn sharp criticism from Judge Chhabria, who underscored the lack of transparency in the Missouri filing and the restrictive opt‑out provisions that could force claimants into a low‑value payout. Opposing plaintiffs’ attorneys argue the agreement primarily enriches a select group of lawyers while offering minimal compensation to the broader pool of affected users. The controversy illustrates the tension between judicial efficiency—ending protracted litigation—and protecting individual litigants’ rights to pursue higher damages in court.

At the same time, Bayer is challenging the very legal foundation of state‑level claims by asking the U.S. Supreme Court to rule that federal law preempts state tort actions when the EPA has not classified glyphosate as a carcinogen. A decision in Bayer’s favor could set a sweeping precedent, limiting future mass‑tort exposures for chemical manufacturers. Conversely, a rejection would reinforce state courts’ authority to hold companies accountable, potentially inflating settlement expectations in similar cases. Stakeholders—from investors to public‑health advocates—are watching closely, as the outcome will influence corporate risk management strategies and the broader regulatory environment for agro‑chemicals.